Chronic obstructive pulmonary disease affects 3.5 million people in France, where it accounts for 17,000 deaths annually according to Inserm data reported by Imaz Press.
The chronic condition causes permanent airway obstruction and progressive breathing difficulty. The World Health Organization ranks the condition as the third leading cause of death worldwide.
“Cette maladie est sous diagnostiquée,” said Morgane Verduyn, a hospital practitioner in the pulmonology department at CHU Nord, in an interview with Imaz Press. Verduyn said that declaration rates for long-term chronic conditions are higher in Réunion than in mainland France, alongside elevated mortality.
Diagnosis relies on respiratory function tests known as spirometry to measure airway obstruction and determine its severity, according to Verduyn. The University Hospital of La Réunion has scheduled prevention events for World COPD Day on November 18, 2026. Patients face persistent symptoms including chronic coughing, daily or near-daily phlegm, fatigue, and recurrent bronchial infections known as exacerbations.
Marie Bruyneel, head of the pulmonology department at CHU Saint-Pierre in Brussels, told L’Avenir that these flare-ups accelerate the irreversible decline of respiratory function. “One of the major problems with COPD is the exacerbations, which accelerate the deterioration of respiratory function and can severely impair quality of life,” Bruyneel told L’Avenir. Infections from viruses and bacteria trigger the majority of these episodes, she added.

The condition costs healthcare insurance 6.4 billion euros in 2023, according to estimates from the Belgian Society of Pneumology cited by L'Avenir. Hospitalizations driven by acute flare-ups generate the highest expenses.
“Ce sont les hospitalisations consécutives aux poussées, la plupart du temps aux soins intensifs, qui engendrent les dépenses les plus importantes,” Bruyneel told L’Avenir.
She said that heart attacks and strokes can follow these acute respiratory episodes within days or weeks.
Health authorities recommend annual influenza vaccinations and pneumococcal vaccines every five years for patients with chronic respiratory failure. Treatment requires smoking cessation and the removal of exposure to hazardous pollutants, alongside appropriate inhaler therapy.